Shiyuan Hong

Dr. Shiyuan Hong

Chongqing Medical University
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YCYixuan Cen
Yixuan Cen
YFYifeng Fang
Yifeng Fang
YRYan Ren
Yan Ren
SHShiyuan Hong
Shiyuan Hong
WLWeiguo Lu
Weiguo Lu
JXJunfen Xu
Junfen Xu
High grade serous ovarian cancer (HGSOC) is the most aggressive subtype of ovarian cancer and HGSOC patients often appear with metastasis, leading to the poor prognosis. Up to date, the extrachromosomal circular DNAs (eccDNAs) have been shown to be involved in cancer genome remodeling but the roles of eccDNAs in metastatic HGSOC are still not clear. Here we explored eccDNA profiles in HGSOC by Circle-Sequencing analysis using four pairs of primary and metastatic tissues of HGSOC patients. Within the differentially expressed eccDNAs screened out by our analysis, eight candidates were validated by outward PCR and qRT-PCR analysis. Among them, DNMT1circle10302690-10302961 was further confirmed by FISH assay and BaseScope assay, as the most significantly down-regulated eccDNA in metastatic tumors of HGSOC. Lower expression of DNMT1circle10302690-10302961 in both primary and metastatic tumors was associated with worse prognosis of HGSOC. Taken together, our finding firstly demonstrated the eccDNAs landscape of primary and metastatic tissues of HGSOC. The eccDNA DNMT1circle10302690-10302961 can be considered as a potential biomarker or a therapeutically clinical target of HGSOC metastasis and prognosis.

22 September 2021 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
JXJunfen Xu
Junfen Xu
YSYuanming Shen
Yuanming Shen
CWConghui Wang
Conghui Wang
STSangsang Tang
Sangsang Tang
SHShiyuan Hong
Shiyuan Hong
XCXiaodong Cheng
Xiaodong Cheng
The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors show survival benefits in ovarian cancer patients withBRCA1/2mutation or homologous recombination (HR) deficiency, but only limited efficacy in HR-proficient ones. Another drug, arsenic trioxide (ATO) or arsenic drug (RIF), exerts antitumor effects via inducing DNA damage. Here, we investigated the combined therapeutic effects of the PARP inhibitors and the arsenic compound in HR-proficient ovarian cancer. The combined treatment of niraparib, olaparib, or fluazolepali with ATO showed a significant suppression in tumor cell viability and colony formation. The drug treatment also induced synergistic inhibition of cell proliferation and DNA damage, and acceleration of cell apoptosis in two HR-proficient ovarian cancer cell lines SKOV3 and CAOV3, either by simultaneous or sequential administration. The mechanism underlying these synergistic effects were reflected by the significantly increased ratio of cleaved-PARP/total PARP and decreased ratio of p-AKT/total AKT. Consistently, the combination of olaparib with RIF synergistically reduced the tumor growth in mouse xenograft models. In conclusion, the arsenic compound greatly sensitizes HR-proficient ovarian cancer cells to the PARP inhibitors, and our findings provide an evidence for the clinical treatment development of this combination in HR-proficient ovarian cancer patients.

25 August 2020 in mBio
Verified
Journal Article
Open access
PDF file
SHShiyuan Hong
Shiyuan Hong
YLYan Li
Yan Li
PKPaul J. Kaminski
Paul J. Kaminski
JAJorge Andrade
Jorge Andrade
Laimonis LaiminsLaimonis Laimins
Laimonis Laimins
High-risk human papillomaviruses (HPVs) infect epithelial cells and induce viral genome amplification upon differentiation. HPV proteins activate the ATR DNA damage repair pathway, and this is required for HPV genome amplification. In the present study, we show that HPV-induced ATR activation also leads to suppression of expression of inflammatory response genes. This suppression results from HPV-induced phosphorylation of the autophagosome cargo protein p62 which regulates the levels of the transcription factor GATA4. Activation of p62 in normal fibroblasts results in senescence, but this is not seen in HPV-positive keratinocytes. Importantly, knockdown of p62 or overexpression of GATA4 in HPV-positive cells abrogates viral replication. This study demonstrates that activation of ATR in HPV-positive cells triggers a p62-directed pathway inducing suppression of inflammatory gene expression independent of DNA repair and facilitating HPV replication.

23 February 2021 in mBio
Verified
Journal Article
Open access
PDF file
PKPaul Kaminski
Paul Kaminski
SHShiyuan Hong
Shiyuan Hong
TKTakeyuki Kono
Takeyuki Kono
PHPaul Hoover
Paul Hoover
Laimonis LaiminsLaimonis Laimins
Laimonis Laimins
High-risk human papillomaviruses (HPVs) infect epithelial cells and induce viral genome amplification upon differentiation. HPV proteins activate DNA damage repair pathways by inducing high numbers of DNA breaks in both viral and cellular DNAs.

10 January 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
SHShiyuan Hong
Shiyuan Hong
JXJunfen Xu
Junfen Xu
YLYan Li
Yan Li
JAJorge Andrade
Jorge Andrade
PHPaul Hoover
Paul Hoover
Laimonis LaiminsLaimonis Laimins
Laimonis Laimins

2 August 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YLYing Luo
Ying Luo
MNMengda Niu
Mengda Niu
YLYanfei Liu
Yanfei Liu
MZMiaochang Zhang
Miaochang Zhang
YDYuanyuan Deng
Yuanyuan Deng
SHShiyuan Hong
Shiyuan Hong
Background: Cervical cancer (CC) stands as a significant health threat to women globally, with high-risk human papillomaviruses as major etiologic agents. The DNA damage repair (DDR) protein topoisomerase I (TOP1) has been linked to various cancers, yet its distinct roles and mechanisms in CC are not fully elucidated.Methods: We investigated TOP1 expression in cervical intraepithelial neoplasia (CIN) and CC tissues utilizing qRT-PCR and IHC, correlating findings with patient prognosis. Subsequent knockdown studies were performed in vitro and in vivo to evaluate the influence of TOP1 on tumor growth, DNA repair, and inflammatory responses.Results: TOP1 was highly expressed in CIN and CC, negatively correlating with patient prognosis. Inhibition of TOP1 impeded CC cell growth and disrupted DNA repair. TOP1 was shown to regulate tumor-promoting inflammation and programmed death-ligand 1 (PD-L1) production in a cGAS-dependent manner. HPV oncoproteins E6 and E7 upregulated TOP1 and activated the cGAS-PD-L1 pathway.Conclusions: TOP1 acts as a DNA repair mediator, promoting CC development and immune evasion. Targeting the TOP1-cGAS-PD-L1 axis could be a potential therapeutic strategy for CC.